Abstract WP197: Poor Venous Outflow is Associated With Ischemic Core Growth During Transfer in Acute Ischemic Stroke Patients With a Large Vessel Occlusion

Aroosa Zamarud,Pierre Seners,Michael Mlynash,Anke Wouters,Leonel Lugo,Tobias Faizy,Maarten G Lansberg,Gregory W Albers,Jeremy J Heit
DOI: https://doi.org/10.1161/str.55.suppl_1.wp197
IF: 10.17
2024-02-01
Stroke
Abstract:Introduction: Thrombectomy is an effective therapy for the treatment of acute ischemic stroke due to large vessel occlusion (AIS-LVO). Patients with small ischemic cores have the most favorable outcomes after thrombectomy, and core growth during the transfer from a primary to a comprehensive stroke center (PSC to CSC) can lead to worse outcomes. We determined if poor venous outflow (VO) prior to transfer to a CSC predicts ischemic core growth in AIS-LVO. Methods: AIS-LVO patients in the prospective CRISP2 study who had a CTA and CT perfusion (CTP) at a PSC and a follow-up CTP or MRI immediately after transfer to the CSC were screened for enrollment. VO was measured on CTA at the PSC using cortical venous opacification score (COVES). COVES 0-2 was defined as unfavorable VO (VO-) and 3-6 was defined as favorable (VO+). Ischemic core was determined on CTP at the PSC and DWI MRI or CTP at the CSC. The primary outcome was inter-hospital ischemic core growth rate defined as a ratio between core growth and time between scans. Results: 174 patients were included; 64% had VO+ and 36% had VO-. VO- patients had larger baseline ischemic core volumes (median 10.5 [IQR 0-23.3] vs 0 [IQR 0-11] ml, p=0.006) and worse CTA collaterals (TAN median 1.82 [IQR 0-3] vs 2.26 [IQR 1-3], p=0.0002). VO- experienced greater ischemic core growth (median 19.6 ml [IQR 2.5-38] vs 8.8 ml [IQR 1.5-21.7], p=0.005) and higher growth rate (median 5.7 ml/hr [IQR 1.4-13.4] vs 2.8 ml/hr [IQR 0.4-7.5], p=0.007) during transfer as described in Figure 1 . Conclusions: In AIS-LVO patients, VO- prior to transfer to a comprehensive stroke center correlated with increased ischemic core growth and more rapid core growth rates. These results have implications for neuroprotection trial design.
peripheral vascular disease,clinical neurology
What problem does this paper attempt to address?